Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

132 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Hepatocellular carcinoma.
Forner A, Llovet JM, Bruix J. Forner A, et al. Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20. Lancet. 2012. PMID: 22353262 Review.
Prognostic prediction in patients with hepatocellular carcinoma.
Sala M, Forner A, Varela M, Bruix J. Sala M, et al. Among authors: forner a. Semin Liver Dis. 2005;25(2):171-80. doi: 10.1055/s-2005-871197. Semin Liver Dis. 2005. PMID: 15918146 Review.
It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, intermediate, advanced, and end-stage categories, provides a link to treatment indication....
It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, interm …
Treatment of hepatocellular carcinoma.
Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Forner A, et al. Crit Rev Oncol Hematol. 2006 Nov;60(2):89-98. doi: 10.1016/j.critrevonc.2006.06.001. Epub 2006 Jul 24. Crit Rev Oncol Hematol. 2006. PMID: 16860993 Review.
There is not a widely accepted HCC staging system. In our group we have developed a new staging classification that stratifies HCC patients into four major categories and simultaneously links staging with treatment. Patients at an early stage are those who present w …
There is not a widely accepted HCC staging system. In our group we have developed a new staging classification that stratifies …
Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure.
Varela M, Forner A, Bruix J. Varela M, et al. Among authors: forner a. Liver Transpl. 2006 Oct;12(10):1445-7. doi: 10.1002/lt.20909. Liver Transpl. 2006. PMID: 17004255 No abstract available.
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Varela M, et al. Among authors: forner a. J Hepatol. 2007 Mar;46(3):474-81. doi: 10.1016/j.jhep.2006.10.020. Epub 2006 Nov 29. J Hepatol. 2007. PMID: 17239480 Clinical Trial.
METHODS: Twenty-seven Child-Pugh A cirrhotics (76% male, 59% HCV) with untreated large/multifocal HCC received chemoembolization with doxorubicin loaded DEBs at doses adjusted for bilirubin and body surface (range: 47-150 mg). ...After a median follow-up of 27.6 mon …
METHODS: Twenty-seven Child-Pugh A cirrhotics (76% male, 59% HCV) with untreated large/multifocal HCC received chemoembolization with …
Transarterial chemoembolization for patients with hepatocellular carcinoma.
Forner A, Real MI, Varela M, Bruix J. Forner A, et al. Hepatol Res. 2007 Sep;37 Suppl 2:S230-7. doi: 10.1111/j.1872-034X.2007.00190.x. Hepatol Res. 2007. PMID: 17877488
Several therapies have been proposed for patients who cannot benefit from a radical approach, but only transarterial chemoembolization has demonstrated survival benefits. ...The objective responses after procedure vary between 20% and 50%, with a significant rate of …
Several therapies have been proposed for patients who cannot benefit from a radical approach, but only transarterial chemoembolizatio …
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.
Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Forner A, et al. Hepatology. 2008 Jan;47(1):97-104. doi: 10.1002/hep.21966. Hepatology. 2008. PMID: 18069697 Clinical Trial.
We included 89 patients with cirrhosis [median age, 65 years; male 53, hepatitis C virus 68, Child-Pugh A 80] without prior hepatocellular carcinoma (HCC) in whom US detected a small solitary nodule (mean diameter, 14 mm). ...Thus, diagnosis of HCC 20 mm or smaller …
We included 89 patients with cirrhosis [median age, 65 years; male 53, hepatitis C virus 68, Child-Pugh A 80] without prior hepatocel …
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: forner a. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Clinical Trial.
A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. ...Seven patients in the sorafenib group (2%)
A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the p
East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma.
Forner A, Bruix J. Forner A, et al. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan;6(1):14-5. doi: 10.1038/ncpgasthep1300. Epub 2008 Nov 4. Nat Clin Pract Gastroenterol Hepatol. 2009. PMID: 18981995 No abstract available.
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group. Mazzaferro V, et al. Among authors: forner a. Lancet Oncol. 2009 Jan;10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5. Epub 2008 Dec 4. Lancet Oncol. 2009. PMID: 19058754
However, survival for patients with cancers that exceed these criteria remains unpredictable and access to transplantation is a balance of maximising patients' chances of cure and organ availability. ...The secondary aim was the identification of a subgroup of patie …
However, survival for patients with cancers that exceed these criteria remains unpredictable and access to transplantation is a balan …
132 results
Jump to page
Feedback